Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies

NCT05094206 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT05094206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05094206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2022
Completion date
January 29, 2024
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia, b-cell non hodgkin lymphoma